Morgan Stanley Raises Glaxo (GSK) to Equalweight, Downgrades AstraZeneca (AZN) by Two Notches to Underweight
Tweet
Share
E-mailGet Alerts GSK Hot Sheet
Price: $52.41 +0.87%
Rating Summary:
6 Buy, 16 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
6 Buy, 16 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Shares of GlaxoSmithKline (NYSE: GSK) and AstraZeneca (NYSE: AZN) have been trading in opposite directions since a mid-day call from a Morgan Stanley analyst.
The analyst upgraded shares of Glaxo from Underweight to Equalweight while at the same time downgrading AstraZeneca shares by two notches from Overweight to Underweight.
Shares of Glaxo last traded at $44.06, down about 0.8 percent from Friday's close. AstraZeneca shares are currenly down 1.5 percent to $47.05. Notably, Glaxo shares are about flat from where the stock opened this morning, however AstraZeneca shares are down nearly 0.7 percent from the open.
To track all the market-moving upgrades/downgrades each day, visit our Ratings Insider portal.
The analyst upgraded shares of Glaxo from Underweight to Equalweight while at the same time downgrading AstraZeneca shares by two notches from Overweight to Underweight.
Shares of Glaxo last traded at $44.06, down about 0.8 percent from Friday's close. AstraZeneca shares are currenly down 1.5 percent to $47.05. Notably, Glaxo shares are about flat from where the stock opened this morning, however AstraZeneca shares are down nearly 0.7 percent from the open.
To track all the market-moving upgrades/downgrades each day, visit our Ratings Insider portal.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Beike (BEKE) PT Raised to $23 at Morgan Stanley
- JPMorgan Downgrades Limbach Holdings (LMB) to Underweight
- Deutsche Bank Downgrades Straumann Holding AG (STMN:SW) (SAUHF) to Hold
Create E-mail Alert Related Categories
Downgrades, UpgradesRelated Entities
Morgan StanleySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
